source
- FAIR Act could boost U.S. rare‑disease trial access and restore biotech leadershipIn a recent BioSpace podcast, host Jennifer C. Smith‑Parker talked with Max Bronstein of Aviva Strategies and Teresa Barnes of PF Warriors about a growing problem: U.S. patients are increasingly un…
- Boehringer's obesity drug shows up to 9.8% weight loss in diabetes patients but lags behind competitorsBoehringer Ingelheim presented data at the European Association for the Study of Diabetes (EASD) meeting in Milan, showing its lead obesity candidate achieved up to 9.8% weight reduction in a late-…